22. Pharmacokinetics/Pharmacodynamics Expert Meeting
From May 3 till May 5, 2018
Event location: Lenzkirch-Saig
Presentations and associated discussions will focus on the following topics:
- Advancement of PK and PKPD aspects of biologics
- "Kidney reloaded”
- Status Update and Challenges of Cancer Immunotherapy
Since 2012 generous donations have enabled the Organizing Committee of the PK/PD Expert Meeting to reward outstanding
contributions by young scientists to the PK/PD field with the Hans Günter Schäfer Award issued in memory of the original initiator of the PK/PD Expert Meeting.
In this year, we would like to congratulate
Dr Miro Eigenmann, translational Modeling and Simulation, Pharmaceutical Sciences, Roche Pharma Research and Early Development,
Roche Innovation Center Basel, for his publication "Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and
physiologically-based pharmacokinetic modelling approaches", J Physiol. 2017 Dec 15;595(24):7311-7330. doi: 10.1113/JP274819.( Link )
We thank the anonymous donor for the sponsorship of this award which included free participation at the
PK/PD Expert Meeting and the opportunity to present key results of their work during the meeting in addition to the prize money.
We look forward to see you at our next meeting in 2019!
Kind regards,
Dr. Antje Walz
on behalf of the Organizing Committee
The programme of the 22. Pharmacokinetics/Pharmacodynamics Expert Meeting
|
Thursday, May 03rd, 2018 |
||
| 17:00 - 19:00 | Arrival Hotel Saigerhöh 79853 Lenzkirch - Saig |
|
| 19:00 | Dinner |
|
|
|
||
| 08:30 | Welcome Antje Walz (Roche) on behalf of the Organizing Committee |
|
|
Session 1: |
Advancement of PK and PKPD aspects of biologics |
|
| 08:40 | The Lymphatic System: Anatomy, physiology and its relevance for mAbs Tine Karlsen, University of Bergen, Norway |
|
| 09:20 | Discussion | |
| 09:35 | Safe starting dose selection for biologics in First-in-Human Studies Ben-Fillippo Krippendorff, Roche |
|
| 10:00 | Discussion | |
| 10:10 | Coffee break | |
| 10:40 | Immunogenicity – challenges for development and to overcome those Daniel Kramer, Sanofi |
|
| 11:05 | Discussion | |
| 11:15 | Mechanistic PKPD modeling for biologics to guide early clinical trials Phil Lowe, Novartis |
|
| 11:40 | Discussion | |
| 12:00 | Joint Lunch |
|
|
Session 2: |
"Kidney reloaded" |
|
| 13:30 | Session Chairs: Corina Becker (Bayer), Wolfgang Mück (Bayer) Thilo Krüger, Bayer |
|
| 13:55 | Discussion | |
| 14:00 | New Insights in the role of kidney: Advances and current limitations of PBPK modeling of impaired renal function Thomas Essing, Bayer |
|
| 14:25 | Discussion | |
| 14:30 | Out of the practice: Best ways to estimate renal function – translation to pharmacotherapy David Czock, University of Heidelberg |
|
| 14:55 | Discussion | |
| 15:10 | Coffee break |
|
| 15:40 | Vericiguat: a Clinical PK example for renal excretion & metabolism Corina Becker, Bayer |
|
| 16:00 | Discussion | |
| 16:10 | Empagliflozin: Impact of kidney disease on PK, biomarker and clinical endpoints Silke Retlich, Boehringer Ingelheim |
|
| 16:30 | Discussion | |
| 16:40 | Hans Günter Schäfer Award Moderated by Antje Walz, Roche |
|
| 17:10 | End of Session | |
| 17:30 | Joint Jogging | |
| 19:00 | Dinner |
|
|
|
||
|
Session 3: |
Status Update and Challenges of Cancer Immunotherapy (CIT) |
|
| 09:00 | Introduction – Overview of current status of cancer immunotherapy Markus Joerger, St Gallen, Switzerland |
|
| 09:30 | Discussion | |
| 09:45 | Challenges of preclinical animals models for Cancer Immunotherapy David Richards, Apogenix |
|
| 10:15 | Discussion | |
| 10:30 | Coffee break | |
| 11:00 | How to translate from animal to man – dose finding and endpoints in early clinical development Andreas Lindauer, SGS |
|
| 11:25 | Discussion | |
| 11:35 | Cancer immunotherapy combination therapy – approaches and challenges for clincal development Benjamin Ribba, Roche |
|
| |
12:00 | Discussion |
| |
12:10 | Concluding Remarks Antje Walz, Roche |
| |
12:15 | Joint Lunch |
| 14:00 | End of Meeting |
|
